drugset / Trial / NCT00211159

OmegAD (Omega-3 and Alzheimer's Disease)

NCT00211159 ↗

Completed 204 enrolled Karolinska University Hospital
RandomizedCrossoverDouble-blindTreatment

Summary

Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients

Timeline

Start
2000-12
Primary completion
—
Completion
—

Outcome

Missed primary endpoint

paper did not delay the rate of cognitive decline according to the MMSE or the cognitive portion of the Alzheimer Disease Assessment Scale. PMID 17030655 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject EPAX 1050TG Other / unclassified 2.3 g Oral

Indications